Therapeutic applications of thymosin peptides: a patent landscape 2018-present.

Abstract

INTRODUCTION:

Thymosins are small proteins found mainly in the thymus. They are involved in several biological processes, including immunoregulation, angiogenesis, and anti-inflammatory activity. Due to these multiple activities, thymosins are widely used as therapeutics. In fact, these peptides have shown interesting results in the treatment of eye disorders, anticancer therapy, and dysregulated immune disorders.

AREA COVERED:

We analyzed the thymosins therapeutic patent landscape describing the most significant patents published after 2018 and originally written in English, classified according to the different type of functions and diseases. We searched 'Thymosin' on Patentscope and Espacenet.

EXPERT OPINION:

Thymalfasin (Zadaxin) is the only FDA-approved thymosine-based drug used to treat chronic hepatitis B and C and as a chemotherapy inducer. This outcome demonstrates how thymosins can be exploited as therapeutics, especially in immunological and anti-cancer therapies. However, the development of modified thymosins could expand their therapeutic interest and application in different diseases. In fact, by chemical modifications, it is possible to increase proteolytic stability in the biological environment, enhance cell permeability, and stabilize the secondary structure of the peptide. Finally, the development of shorter sequences could reduce the cost and production time of these thymosin-based drugs.

• Authors: Michael Quagliata, Anna Maria Papini, Paolo Rovero
• Journal: Expert opinion on therapeutic patents (Expert Opin Ther Pat) Vol. 33 Issue 12 Pg. 865-873 (Dec 2023) ISSN: 1744-7674 [Electronic] England
• PMID: 38131310 (Publication Type: Journal Article, Review)

Chemical References

• Thymosin

Topics

• Humans
• Patents as Topic
• Thymosin (pharmacology, chemistry, metabolism)
• Thymus Gland